Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. (2022)

First Author: Chanchlani N
Attributed to:  King's Health Partners Confidence in Concept funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/ecco-jcc/jjab153

PubMed Identifier: 34473254

Publication URI: http://europepmc.org/abstract/MED/34473254

Type: Journal Article/Review

Volume: 16

Parent Publication: Journal of Crohn's & colitis

Issue: 3

ISSN: 1873-9946